Strategic acquisitions will continue to drive mid-market M&A

20 September 2016

In our weekly expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, explains why we can expect mid-market companies to press on with their expansion through strategic transactions for the remainder of 2016.

While mega deals have dominated pharma M&A so far this year, mid-market M&A transactions have also been strong and are tipped to gather pace over the rest of this year. The main drivers fueling this activity have been the hunt for strategic opportunities, search for innovation, dwindling product pipelines, and attractive valuations of pharmaceutical companies.

Rise of the mega deals in the pharma sector..

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK